Pruritus - Pipeline Review, H2 2016

Choose Licence

 

Pruritus - Pipeline Review, H2 2016 Summary Global Markets Directs, Pruritus - Pipeline Review, H2 2016?, provides an overview of the Pruritus pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pruritus - The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects - The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pruritus Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pruritus - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pruritus Overview 10 Therapeutics Development 11 Pipeline Products for Pruritus - Overview 11 Pipeline Products for Pruritus - Comparative Analysis 12 Pruritus - Therapeutics under Development by Companies 13 Pruritus - Therapeutics under Investigation by Universities/Institutes 15 Pruritus - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pruritus - Products under Development by Companies 19 Pruritus - Products under Investigation by Universities/Institutes 21 Pruritus - Companies Involved in Therapeutics Development 22 Albireo AB 22 Alveonix AG 23 Amorepacific Corporation 24 Asana BioSciences, LLC 25 Cara Therapeutics, Inc. 26 Chugai Pharmaceutical Co., Ltd. 27 Creabilis SA 28 ELORAC, Inc. 29 Faes Farma, S.A. 30 GlaxoSmithKline Plc 31 Hydra Biosciences, Inc. 32 LEO Pharma A/S 33 Merck & Co., Inc. 34 NeRRe Therapeutics Ltd 35 Nippon Shinyaku Co., Ltd. 36 Patara Pharma, Inc. 37 Phosphagenics Limited 38 RDD Pharma Ltd. 39 Sanwa Kagaku Kenkyusho Co., Ltd. 40 Shionogi & Co., Ltd. 41 Sumitomo Dainippon Pharma Co., Ltd. 42 Teikoku Pharma USA, Inc. 43 Tioga Pharmaceuticals, Inc. 44 Trevi Therapeutics, Inc. 45 Vanda Pharmaceuticals Inc. 46 Pruritus - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 A-4250 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 aprepitant - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 asimadoline - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 ASN-008 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Ax-10 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Ax-8 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 bilastine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 cromolyn sodium - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 CT-327 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 CT-340 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 desloratadine - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 difelikefalin - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 GSK-2330672 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 lidocaine hydrochloride - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 nalbuphine hydrochloride ER - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 naloxone hydrochloride - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 nemolizumab - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 NS-141 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 orvepitant maleate - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 PAC-14028 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Peptides to Target TRPV1 for Pain and Itch - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 RDD-1609 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 serlopitant - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 SK-1405 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Small Molecule to Agonize CB2 for Pruritus - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Small Molecule to Inhibit Substance P for Pruritus - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 TPU-010 - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 tradipitant - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Pruritus - Dormant Projects 107 Pruritus - Discontinued Products 109 Pruritus - Product Development Milestones 110 Featured News & Press Releases 110 Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings 110 Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting 110 Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference 111 Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain 112 Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis 112 May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 113 Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids 114 Mar 19, 2015: Creabilis? CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 114 Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 115 Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration 117 Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients 117 Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 118 Aug 06, 2014: Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus 119 Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting 119 Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors 120 Appendix 122 Methodology 122 Coverage 122 Secondary Research 122 Primary Research 122 Expert Panel Validation 122 Contact Us 122 Disclaimer 123

List of Tables Number of Products under Development for Pruritus, H2 2016 11 Number of Products under Development for Pruritus - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Development by Companies, H2 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Pruritus - Pipeline by Albireo AB, H2 2016 22 Pruritus - Pipeline by Alveonix AG, H2 2016 23 Pruritus - Pipeline by Amorepacific Corporation, H2 2016 24 Pruritus - Pipeline by Asana BioSciences, LLC, H2 2016 25 Pruritus - Pipeline by Cara Therapeutics, Inc., H2 2016 26 Pruritus - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 27 Pruritus - Pipeline by Creabilis SA, H2 2016 28 Pruritus - Pipeline by ELORAC, Inc., H2 2016 29 Pruritus - Pipeline by Faes Farma, S.A., H2 2016 30 Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2016 31 Pruritus - Pipeline by Hydra Biosciences, Inc., H2 2016 32 Pruritus - Pipeline by LEO Pharma A/S, H2 2016 33 Pruritus - Pipeline by Merck & Co., Inc., H2 2016 34 Pruritus - Pipeline by NeRRe Therapeutics Ltd, H2 2016 35 Pruritus - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 36 Pruritus - Pipeline by Patara Pharma, Inc., H2 2016 37 Pruritus - Pipeline by Phosphagenics Limited, H2 2016 38 Pruritus - Pipeline by RDD Pharma Ltd., H2 2016 39 Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 40 Pruritus - Pipeline by Shionogi & Co., Ltd., H2 2016 41 Pruritus - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 42 Pruritus - Pipeline by Teikoku Pharma USA, Inc., H2 2016 43 Pruritus - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016 44 Pruritus - Pipeline by Trevi Therapeutics, Inc., H2 2016 45 Pruritus - Pipeline by Vanda Pharmaceuticals Inc., H2 2016 46 Assessment by Monotherapy Products, H2 2016 47 Number of Products by Stage and Target, H2 2016 49 Number of Products by Stage and Mechanism of Action, H2 2016 51 Number of Products by Stage and Route of Administration, H2 2016 54 Number of Products by Stage and Molecule Type, H2 2016 56 Pruritus - Dormant Projects, H2 2016 107 Pruritus - Dormant Projects (Contd..1), H2 2016 108 Pruritus - Discontinued Products, H2 2016 109


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports